Press Releases – NASDAQ (US) Website

Press Releases

Sep 20, 2018
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology    read more...
Sep 16, 2018
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology    read more...
Sep 07, 2018
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors    read more...
Sep 05, 2018
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto    read more...
Sep 04, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)    read more...
Sep 04, 2018
BeiGene to Present at the Morgan Stanley 16th Annual Global Healthcare Conference    read more...
Aug 31, 2018
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China    read more...
Aug 26, 2018
BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration    read more...
Aug 09, 2018
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China    read more...
Aug 09, 2018
BeiGene Reports Second Quarter 2018 Financial Results    read more...
Aug 08, 2018
BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering    read more...
Aug 02, 2018
BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering    read more...
Jul 27, 2018
BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering    read more...
Jul 24, 2018
BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China    read more...
Jul 24, 2018
BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer    read more...
Jul 22, 2018
BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma    read more...
Jul 22, 2018
BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM)    read more...
Jul 20, 2018
BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited    read more...
Jul 03, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)    read more...
Jun 15, 2018
BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association    read more...